文献速递神经免疫

3例多发性硬化患者在接受阿仑单抗治疗期间出现疾病激活

Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis.
PubMed 文献 · Neurology · 2018-01-19

本文为回顾性病例系列,报告3例多发性硬化患者在阿仑单抗免疫治疗诱导后6个月出现严重疾病激活,均表现为症状复发、MRI新发病灶(部分呈钆环形强化)及B淋巴细胞占优,总B细胞计数出乎意料地高,作者推测可能存在B细胞介导的疾病激活。

要点

  • 3例均在阿仑单抗诱导后6个月出现疾病激活,MRI病灶形态高度相似。
  • 病灶部分呈钆环形强化,并见CD19/20阳性B淋巴细胞占优。
  • 作者推测B细胞介导的疾病激活可能与B、T细胞再增殖速率不同有关。

核心结论

  • 本文报告3例多发性硬化患者在接受阿仑单抗免疫治疗期间出现严重疾病激活,均在诱导后6个月起病,作者认为可能提示B细胞介导的疾病激活。

研究设计与样本

  • 回顾性病例系列,纳入3例多发性硬化患者,报告其在阿仑单抗免疫治疗期间出现的疾病激活表现。

主要发现

  • 患者1为21岁女性,阿仑单抗诱导后6个月出现严重认知障碍、视力下降、严重步态共济失调、尿潴留及脑病灶负荷广泛进展,新病灶呈钆环形强化并见CD19/20阳性B淋巴细胞占优。
  • 患者2为28岁男性,阿仑单抗诱导后6个月出现左侧偏身感觉减退及约60个新发脑和脊髓病灶,其中部分病灶呈钆环形强化。
  • 患者3为37岁女性,阿仑单抗诱导后6个月出现共济失调和左大腿麻木,出现16个新发钆强化幕上病灶,部分呈环形强化并见CD19/20阳性B淋巴细胞占优。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出,这是否源于B细胞与T细胞再增殖速率不同,尚需进一步研究。
  • 原文指出,适应性免疫与固有免疫之间以及B细胞与T细胞谱系之间相互作用的进一步影响,或可解释所观察到的疾病激活。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report 3 patients with multiple sclerosis showing severe activation of disease during immunotherapy with alemtuzumab. METHODS: Retrospective case series. RESULTS: Patient 1, a 21-year-old woman, developed severe cognitive impairment, sight deterioration, severe gait ataxia, urinary retention, and extensive progression of cerebral lesion load, including new lesions that exhibited gadolinium ring enhancement and dominance of CD19/20-positive B lymphocytes, 6 months after induction of alemtuzumab. Patient 2, a 28-year-old man, developed left-sided hemihypesthesia and ∼60 new cerebral and spinal lesions including lesions with gadolinium ring enhancement 6 months after induction of alemtuzumab. Patient 3, a 37-year-old woman, developed ataxia and numbness of the left thigh, 16 new gadolinium-positive supratentorial lesions, and partly ring-enhancing and dominance of CD19/20-positive B lymphocytes 6 months after induction of alemtuzumab. CONCLUSION: This is a case series reporting severe activation of disease during immunotherapy with alemtuzumab. All patients showed onset of symptoms 6 months after induction of alemtuzumab, strikingly similar MRI lesion morphology, and unexpected high total B cell count, which may suggest a B-cell-mediated activation of disease. Whether this is due to different rates of B- and T cell repopulation has to be the subject of further research. Moreover, further effects on the interactions between the adaptive and innate immunity as well as between B and T cell lineages might explain the observed disease activation.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Wehrum T, Beume LA, Stich O, et al. Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis. Neurology. 2018. PMID: 29352101. doi:10.1212/WNL.0000000000004950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。